Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model

Area of Science:

• Immunology
• Endocrinology
• Autoimmunity

Background:

• Autoreactive CD4(+) T cells targeting islet antigens are key drivers of type 1 diabetes.
• Targeting these specific T cells is a crucial strategy for disease cure.

Purpose of the Study:

• To develop a method for generating CD4(+) T cells with antigen-specific apoptosis-inducing capabilities.
• To evaluate the therapeutic potential of these engineered T cells in type 1 diabetes models.

Main Methods:

• Incorporating a thiol-disulfide oxidoreductase (thioreductase) motif into a GAD65 epitope to create GAD65-specific cytolytic CD4(+) T cells (cCD4(+) T).
• Inducing cCD4(+) T cells in vitro and through active immunization in mice.
• Assessing T cell phenotype, APC lysis via Fas-FasL interaction, bystander T cell apoptosis, and in vivo efficacy in a mouse model of type 1 diabetes.

Main Results:

• GAD65-specific cCD4(+) T cells were generated, exhibiting an effector memory phenotype.
• These cCD4(+) T cells effectively lysed antigen-presenting cells (APCs) and induced apoptosis in bystander CD4(+) T cells.
• Active immunization protected mice from type 1 diabetes and reduced insulitis; passive transfer of cCD4(+) T cells suppressed autoimmunity.

Conclusions:

• A novel vaccination strategy using thioreductase-modified T cell epitopes can generate cytolytic CD4(+) T cells.
• These engineered T cells suppress autoimmune responses and prevent type 1 diabetes in preclinical models.
• This approach holds promise for a new therapeutic strategy against type 1 diabetes.